EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieVergleichsstudieOpen Access · CC BY-NC-ND 4.0

Vonoprazan-containing Dual and Triple Therapies are Non-inferior to Bismuth-quadruple Therapy for Helicobacter pylori Eradication: A Single-center, Prospective, Open-label, Real-World Study

Ya-Bin Qi, Xiao-Ting Li, Qiao-Qiao Shao, Lu Xu, Wen-Jing Zhang, Shuai-Bo Song, Qin-Nan Yan, Shi-Yu Shi, Ruo-Bing Hu, Amr Mekky, Chen Zhang, Jing Ma und 7 weitere

Journal of Gastrointestinal and Liver Diseases · 2025

DOI: 10.15403/jgld-6183 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Gastrointestinal and Liver Diseases, 2025. Verfasst von Ya-Bin Qi und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, People's Hospital of Zhengzhou University, and Henan Provincial People's Hospital, Zhengzhou, Henan, 4…. Hauptthemen laut MEDLINE: Helicobacter Infections, Helicobacter pylori, Bismuth, Proton Pump Inhibitors. Die Arbeit wurde bisher 9-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims: Vonoprazan (Vo) and amoxicillin (Amx) dual therapy has shown promising results for Helicobacter pylori (H. pylori) eradication. However, its efficacy needs to be verified in an area with a high prevalence of both H. pylori and gastric cancer. It is also unknown if the modified Vo-Amx plus bismuth (Bis) regimen might increase the eradication rate. We aimed to investigate the efficacy and safety of Vo-Amx and Vo-Amx-Bis regimens, compared to bismuth-containing quadruple therapy (BQT) for H. pylori eradication, as well as factors that affect the curing rate.

Methods

A total of 342 treatment-naïve H. pylori-infected patients were screened and 255 were enrolled and randomized into Vo-Amx, Vo-Amx-Bis, and BQT groups for treatment. H. pylori infection status was determined by 13C-urea breath test. The eradication rate and incidence of adverse events were assessed, and factors that might affect the curing rate were also analyzed.

Results

In per-protocol (PP) analysis, H. pylori eradication rates in Vo-Amx, Vo-Amx-Bis, and BQT groups were 95.1%, 92.7%, and 90.4%, respectively (p>0.05). In intention-to-treat (ITT) analysis, eradication rates in Vo-Amx, Vo-Amx-Bis, and BQT groups were 91.8%, 89.4%, and 88.2%, respectively (p>0.05). The eradication efficacy of Vo-Amx and Vo-Amx-Bis groups was non-inferior to that of BQT group, and the incidence of side effects (including nausea, vomiting, anorexia, abdominal pain, diarrhea, palpitation, dizziness, and debilitation) was lower than that of BQT group (6.1% and 4.9%, vs 45.8%, respectively, p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Helicobacter InfectionsHelicobacter pyloriBismuthProton Pump InhibitorsAmoxicillinAnti-Bacterial AgentsSulfonamidesPyrrolesHumansMaleFemaleMiddle AgedProspective StudiesDrug Therapy, CombinationTreatment OutcomeAgedAdultBreath Tests

Substanzen

1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamineBismuthProton Pump InhibitorsAmoxicillinAnti-Bacterial AgentsSulfonamidesPyrroles

Autor:innen und Institutionen

  • Department of Gastroenterology and Hepatology, People's Hospital of Zhengzhou University, and Henan Provincial People's Hospital, Zhengzhou, Henan, 450003, China.. qiyabin.cool@163.com.
  • People's Hospital of Zhengzhou University, and Henan Provincial People's Hospital, Zhengzhou, Henan, 450003, China.. lxiaoting0617@163.com.
  • Department of Medical Record, People's Hospital of Zhengzhou University, and Henan Provincial People's Hospital, Zhengzhou, Henan, 450003, China.. shaoqq2050@163.com.
  • Department of Gastroenterology and Hepatology, People's Hospital of Zhengzhou University, and Henan Provincial People's Hospital, Zhengzhou, Henan, 450003, China. 549205874@qq.com.
  • Department of Gastroenterology and Hepatology, People's Hospital of Zhengzhou University, and Henan Provincial People's Hospital, Zhengzhou, Henan, 450003, China. zhangwenjing202209@163.com.
  • Department of Gastroenterology and Hepatology, Henan University People's Hospital, and Henan Provincial People's Hospital, Zhengzhou, Henan, 450003, China.. songshuaibo0112@163.com.

Zitieren

APA

Qi, Y. B., Li, X. T., Shao, Q. Q., Xu, L., Zhang, W. J., Song, S. B., Yan, Q. N., Shi, S. Y., Hu, R. B., Mekky, A., Zhang, C., Ma, J., Xiao, W., Li, K., Liu, T. T., Fang, X. H., Zhang, L. D., Yang, G. H., & Ding, S. Z. (2025). Vonoprazan-containing Dual and Triple Therapies are Non-inferior to Bismuth-quadruple Therapy for Helicobacter pylori Eradication: A Single-center, Prospective, Open-label, Real-World Study. Journal of Gastrointestinal and Liver Diseases. https://doi.org/10.15403/jgld-6183

Vancouver

Qi YB, Li XT, Shao QQ, Xu L, Zhang WJ, Song SB, et al. Vonoprazan-containing Dual and Triple Therapies are Non-inferior to Bismuth-quadruple Therapy for Helicobacter pylori Eradication: A Single-center, Prospective, Open-label, Real-World Study. Journal of Gastrointestinal and Liver Diseases. 2025. doi:10.15403/jgld-6183

BibTeX
@article{Qi2025,
  author = {Qi, Ya-Bin and Li, Xiao-Ting and Shao, Qiao-Qiao and Xu, Lu and Zhang, Wen-Jing and Song, Shuai-Bo and Yan, Qin-Nan and Shi, Shi-Yu and Hu, Ruo-Bing and Mekky, Amr and Zhang, Chen and Ma, Jing and Xiao, Wei and Li, Kuan and Liu, Ting-Ting and Fang, Xin-Hui and Zhang, Li-Da and Yang, Guo-Hong and Ding, Song-Ze},
  title = {Vonoprazan-containing Dual and Triple Therapies are Non-inferior to Bismuth-quadruple Therapy for Helicobacter pylori Eradication: A Single-center, Prospective, Open-label, Real-World Study},
  journal = {Journal of Gastrointestinal and Liver Diseases},
  year = {2025},
  doi = {10.15403/jgld-6183}
}
Kostenlos starten →